Results 121 to 130 of about 22,968 (195)

The dynamics of centromere assembly and disassembly during quiescence. [PDF]

J Cell Biol
Marescal O, Su KC, Moodie B, Taylor NJL, Cheeseman IM.   +4 more
europepmc   +1 more source

Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors. [PDF]

Sci Rep
Torrisi R, Giordano L, Pancetti S, Carnaghi C, Basilico V, Palumbo R, Gerosa R, Saltalamacchia G, Sanò MV, Santoro A, Fernandes B.   +10 more
europepmc   +1 more source

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York Cancer Consortium trial [PDF]

, 2016
et al,, Ma, Cynthia X, Naughton, Michael
core   +2 more sources

Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study. [PDF]

Curr Oncol
Rayson D, Bertin J, Lemelin M, Tong M, Ng R, Ding P, Cheung WY, Sharma A, On PV, Feugère G, Lupichuk S.   +10 more
europepmc   +1 more source

Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group. [PDF]

Breast Cancer
Masuda H, Nagai SE, Hattori M, Yoshinami T, Okamura T, Watanabe K, Nakayama T, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Sasada S, Ishida T, Futamura M, Oda H, Muramatsu Y, Masuda N.   +22 more
europepmc   +1 more source

Targeted therapies for ER+/HER2- metastatic breast cancer [PDF]

, 2015

core   +1 more source

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care. [PDF]

Breast Cancer Res Treat
Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH.   +9 more
europepmc   +1 more source

The kinase inhibitor palbociclib binds to HIV TAR RNA with very low nanomolar affinity and exquisite specificity. [PDF]

Nucleic Acids Res
Reddy Ramireddy R, Shortridge MD, Vidalala V, Chaubey B, Tang C, Olsen GL, Varani G.   +6 more
europepmc   +1 more source

Proteome-based molecular subtyping and therapeutic target prediction in cervical cancer. [PDF]

Biomark Res
Yang T, Guo L, Liu D, Hua K, Li C.
europepmc   +1 more source

CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. [PDF]

Nat Commun
Luo L, Wang Y, Bui T, Jiang X, Chen MK, Rao X, Mohammadhosseinpour S, Li M, Kim S, Kim RY, Kamaliasl S, Ulizio CW, Tsavachidis S, Navarro-Yepes J, Kettner NM, Wingate H, Meric-Bernstam F, Hunt KK, Wang J, Faia K, Keyomarsi K.   +20 more
europepmc   +1 more source